13F Pro13F Pro

SEC Form 4 reporting owner

Bonita David P

Bonita David P has filed 12 Form 4 transactions reported between April 14, 2026 and November 16, 2026, as Director of WINDWARD BIO GROUP AG, Director of ImageneBio, Inc. and Director of Prelude Therapeutics Inc.

Name as filed: Bonita David P

Follow Bonita David P and get an alert on every new Form 4

Bonita David P holds 7.1M shares of WWB, worth $167.9M.

As of their Nov 16, 2026 Form 4 (filed Nov 18, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $23.66

Bonita David P holds at least 1.1M shares of PRLD, worth $3.7M, 1.41% of the company.

As of their Apr 21, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $3.27 · 80.1M shares outstanding on Nov 11, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Bonita David P holds at least 384,689 shares of IMA, worth $1.5M, 3.09% of the company.

As of their Apr 14, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $4.00 · 12.5M shares outstanding on Oct 31, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Open-market buys, 24 mo
$12.5M
2 lines
Open-market sales, 24 mo
None
reported
Companies
3
with Form 4 filings
Latest transaction
Nov 16, 2026
transaction date

Roles and reported holdings

  • WWBWINDWARD BIO GROUP AG
    Nov 12, 2026 – Nov 16, 2026

    Director

    See footnotes7,097,483 sh

    Also reports 22,675 Stock Option (right to buy), not counted as shares.

    As of Nov 16, 2026 · Form 4

    1 line is priced far from WWB’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • IMAImageneBio, Inc.
    Apr 14, 2026 – Jun 16, 2026

    Director

    Indirect (latest line that moved)384,689 sh

    As of Apr 14, 2026 · Form 4

  • PRLDPrelude Therapeutics Inc
    Apr 21, 2026 – Jun 9, 2026

    Director

    Indirect (latest line that moved)1,126,126 sh

    As of Apr 21, 2026 · Form 4

    24 months: $12.5M bought

How their buys did since

2 open-market purchases against today’s price: -26.4% on average, -26.4% weighted by dollars spent.

DatePaidReturn
Apr 21, 2026PRLD$4.44-26.4%now $3.27
Apr 21, 2026PRLD$4.44-26.4%now $3.27

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 12 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 16, 2026WWBDirectorShares withheld for tax or exercise priceCode F · indirect232$4K@ $17.00Form 4
Nov 16, 2026WWBDirectorOption exerciseCode M · indirect216,668$4K@ $0.0200Form 4
Nov 16, 2026WWBDirectorConversion of derivativeCode C · indirect1,611,008—Form 4
Nov 16, 2026WWBDirectorConversion of derivativeCode C · indirect3,561,936—Form 4
Nov 16, 2026WWBDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by ORBIMED ADVISORS LLC1,176,471$20.0M@ $17.00Form 4
Nov 12, 2026WWBGrant or awardCode A · direct22,675—Form 4
Jun 16, 2026IMAGrant or awardCode A · direct15,600—Form 4
Jun 9, 2026PRLDGrant or awardCode A · direct38,000—Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,126,126$5.0M@ $4.44Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,689,189$7.5M@ $4.44Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect384,689—Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect336,603—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

1 open-market line is priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.